Aimmune Therapeutics (NASDAQ: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, recently closed its underwritten public offering of 6,325,000 shares of its common stock, which includes the sale of 825,000 shares in accordance with the full exercise of the over-allotment option granted to the underwriters. The shares were sold at a price to the public of $32.00 per share, resulting in the gross proceeds of $202.4 million for the company. Aimmune intends to use the proceeds to fund the advancement of AR101 through clinical development, potential application filings and preparation for budding commercialization. The company also intends to utilize the capital to fund the research and development of additional CODIT™ product candidates and other general corporate purposes.
To view the full press release, visit http://nnw.fm/Dg9E5
About Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age and is currently being evaluated in phase 3 clinical trials. For more information, visit the company’s website at www.aimmune.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com